HIV vasculopathy: Role of mononuclear cell-associated Krü ppel-like factors 2 and 4

AIDS

Volumn 29, Issue 13, 2015, Pages 1643-1650

  Hale, Andrew T ^a,d   Longenecker, Chris T ^a,b   Jiang, Ying ^a   Debanne, Sara M ^a   Labatto, Danielle E ^a,c   Storer, Norma ^a,c   Hamik, Anne ^a,b,d   McComsey, Grace A ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; HIV; Immune activation; Inflammation; Kr ppel like factor

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KRUPPEL LIKE FACTOR 2; KRUPPEL LIKE FACTOR 4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; ANTIRETROVIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT; KLF2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIAC IMAGING; CAROTID ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; FLOW CYTOMETRY; FRAMINGHAM RISK SCORE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED VASCULOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VASCULAR DISEASE; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; CAROTID ARTERY; COMPLICATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; GENE EXPRESSION PROFILING; GENETICS; HEART; HYPERLIPIDEMIAS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; X-RAY COMPUTED TOMOGRAPHY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION PROFILING; HEART; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLACEBOS; REAL-TIME POLYMERASE CHAIN REACTION; ROSUVASTATIN CALCIUM; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84942511411     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000756     Document Type: Article

References (68)

1. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-212.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
3. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205 (Suppl 3):S375-S382.
4. Longenecker CT, Triant VA. Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS 2013; 9:54-62.
5. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-1567.
6. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vi-jayakumar J, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-386.
7. Burdo TH, Lo J, Abbara S, Wei J, Delelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-1236.
8. Longenecker CT, Funderburg NT, Jiang Y, Debanne S, Storer N, Labbato DE, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385-390.
9. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452-463.
10. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011; 217:207-213.
11. Kalayjian RC, Machekano RN, Rizk N, Robbins GK, Gandhi RT, Rodriguez BA, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201:1796-1805.
12. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
13. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
14. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7:77-86.
15. Ancuta P, Wang J, Gabuzda D. CD16R monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol 2006; 80:1156-1164.
16. Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33:375-386.
17. Ziegler-Heitbrock L. The CD14R CD16R blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81:584-592.
18. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 2012; 120:4599-4608.
19. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9:139-147.
20. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
21. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308:788-795.
22. Post WS, Budoff M, Kingsley L, Palella FJ Jr, Witt MD, Li X, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014; 160:458-467.
23. Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, et al. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol 2012; 109:742-747.
24. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-269.
25. Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation 1990; 82:1230-1242.
26. Longenecker C, Jiang Y, Orringer C, Gilkeson R, Debanne S, Funderburg N, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28:969-977.
27. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-1849.
28. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19:927-933.
29. Stein JH, Brown TT, Ribaudo HJ, Chen Y, Yan M, Lauer-Brodell E, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2012; 27:929-937.
30. Nayak L, Goduni L, Takami Y, Sharma N, Kapil P, Jain MK, et al. Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol 2013; 182:1696-1704.
31. Shatat MA, Tian H, Zhang R, Tandon G, Hale A, Fritz JS, et al. Endothelial Kruppel-like factor 4 modulates pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2014; 50:647-653.
32. Nayak L, Shi H, Atkins GB, Lin Z, Schmaier AH, Jain MK. The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2). Blood 2014; 123:3828-3831.
33. Zhou G, Hamik A, Nayak L, Tian H, Shi H, Lu Y, et al. Endothelial Kruppel-like factor 4 protects against atherothrom-bosis in mice. J Clin Invest 2012; 122:4727-4731.
34. Lin Z, Natesan V, Shi H, Dong F, Kawanami D, Mahabeleshwar GH, et al. Kruppel-like factor 2 regulates endothelial barrier function. Arterioscler Thromb Vasc Biol 2010; 30:1952-1959.
35. Atkins GB, Wang Y, Mahabeleshwar GH, Shi H, Gao H, Kawanami D, et al. Hemizygous deficiency of Kruppel-like factor 2 augments experimental atherosclerosis. Circ Res 2008; 103:690-693.
36. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004; 199:1305-1315.
37. Liao X, Sharma N, Kapadia F, Zhou G, Lu Y, Hong H, et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest 2011; 121:2736-2749.
38. Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, et al. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem 2007; 282:13769-13779.
39. Bu DX, Tarrio M, Grabie N, Zhang Y, Yamazaki H, Stavrakis G, et al. Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest 2010; 120:1961-1970.
40. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
41. Hale AT, Tian H, Anih E, Recio FO 3rd, Shatat MA, Johnson T, et al. Endothelial Kruppel-like factor 4 regulates angiogenesis and the Notch signaling pathway. J Biol Chem 2014; 289:12016-12028.
42. Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S, Funderburg NT, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28:969-977.
43. Hart GT, Hogquist KA, Jameson SC. Kruppel-like factors in lymphocyte biology. J Immunol 2012; 188:521-526.
44. Cao Z, Sun X, Icli B, Wara AK, Feinberg MW. Role of Kruppel-like factors in leukocyte development, function, and disease. Blood 2010; 116:4404-4414.
45. Das M, Lu J, Joseph M, Aggarwal R, Kanji S, McMichael BK, et al. Kruppel-like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL-1beta-induced arthritis. Curr Mol Med 2012; 12:113-125.
46. Mahabeleshwar GH, Kawanami D, Sharma N, Takami Y, Zhou G, Shi H, et al. The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock. Immunity 2011; 34:715-728.
47. Kuo CT, Veselits ML, Leiden JM. LKLF: a transcriptional regulator of single-positive T cell quiescence and survival. Science 1997; 277:1986-1990.
48. Buckley AF, Kuo CT, Leiden JM. Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway. Nat Immunol 2001; 2:698-704.
49. Das H, Kumar A, Lin Z, Patino WD, Hwang PM, Feinberg MW, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci USA 2006; 103:6653-6658.
50. Feinberg MW, Cao Z, Wara AK, Lebedeva MA, Senbanerjee S, Jain MK. Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem 2005; 280:38247-38258.
51. Mudd JC, Murphy P, Manion M, Debernardo R, Hardacre J, Ammori J, et al. Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood 2013; 121:2914-2922.
52. Schober SL, Kuo CT, Schluns KS, Lefrancois L, Leiden JM, Jameson SC. Expression of the transcription factor lung Krup-pel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. J Immunol 1999; 163:3662-3667.
53. Richardson MW, Jadlowsky J, Didigu CA, Doms RW, Riley JL. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J Immunol 2012; 189:3815-3821.
54. Trinite B, Chan CN, Lee CS, Mahajan S, Luo Y, Muesing MA, et al. Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells. PLoS One 2014; 9:e110719.
55. Alder JK, Georgantas RW 3rd, Hildreth RL, Kaplan IM, Morisot S, Yu X, et al. Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. J Immunol 2008; 180:5645-5652.
56. Lebson L, Gocke A, Rosenzweig J, Alder J, Civin C, Calabresi PA, et al. Cutting edge: the transcription factor Kruppel-like factor 4 regulates the differentiation of Th17 cells independently of RORgammat. J Immunol 2010; 185:7161-7164.
57. An J, Golech S, Klaewsongkram J, Zhang Y, Subedi K, Huston GE, et al. Kruppel-like factor 4 (KLF4) directly regulates proliferation in thymocyte development and IL-17 expression during Th17 differentiation. FASEB J 2011; 25: 3634-3645.
58. Yamada T, Park CS, Mamonkin M, Lacorazza HD. Transcription factor ELF4 controls the proliferation and homing of CD8R T cells via the Kruppel-like factors KLF4 and KLF2. Nat Immunol 2009; 10:618-626.
59. Baker JV, Hullsiek KH, Singh A, Wilson E, Henry K, Lichtenstein K, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS 2014; 28:831-840.
60. Longenecker C, Jiang Y, Debanne S, McComsey G. Carotid distensibility and immune activation in HIV-infected patients without coronary calcium. In: 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2014.
61. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208:1202-1211.
62. Dekker RJ, van Soest S, Fontijn RD, Salamanca S, de Groot PG, VanBavel E, et al. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2). Blood 2002; 100:1689-1698.
63. Gnasso A, Carallo C, Irace C, Spagnuolo V, De Novara G, Mattioli PL, et al. Association between intima-media thickness and wall shear stress in common carotid arteries in healthy male subjects. Circulation 1996; 94:3257-3262.
64. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-1182.
65. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4:977-987.
66. Maejima T, Inoue T, Kanki Y, Kohro T, Li G, Ohta Y, et al. Direct evidence for pitavastatin induced chromatin structure change in the KLF4 gene in endothelial cells. PLoS One 2014; 9:e96005.
67. Villarreal G Jr, Zhang Y, Larman HB, Gracia-Sancho J, Koo A, Garcia-Cardena G. Defining the regulation of KLF4 expression and its downstream transcriptional targets in vascular en-dothelial cells. Biochem Biophys Res Commun 2010; 391:984-989.
68. Bjorkhem-Bergman L, Lindh JD, Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol 2011; 72:164-165.